Nuveen LLC Buys Shares of 64,381 Dianthus Therapeutics, Inc. $DNTH

Nuveen LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 64,381 shares of the company's stock, valued at approximately $1,168,000. Nuveen LLC owned 0.20% of Dianthus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. MetLife Investment Management LLC boosted its holdings in shares of Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock worth $313,000 after purchasing an additional 433 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Dianthus Therapeutics by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock worth $1,336,000 after purchasing an additional 748 shares during the period. Invesco Ltd. boosted its holdings in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after purchasing an additional 790 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Dianthus Therapeutics by 0.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company's stock worth $3,049,000 after purchasing an additional 1,081 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company's stock worth $933,000 after purchasing an additional 1,082 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

DNTH traded up $1.84 on Friday, hitting $26.50. The company had a trading volume of 679,673 shares, compared to its average volume of 340,531. The company's fifty day moving average price is $21.27 and its 200 day moving average price is $20.06. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $32.27. The stock has a market cap of $853.04 million, a price-to-earnings ratio of -8.15 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on DNTH shares. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Robert W. Baird dropped their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Wedbush increased their price objective on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Finally, William Blair started coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Buy" and a consensus target price of $54.00.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.